Navigation Links
Bio-Eye Hydroxyapatite (HA) Orbital Implant

ProductsBio-Eye Hydroxyapatite (HA) Orbital Implant
Company Bio-Eye Orbital Implants
Item Bio-Eye Hydroxyapatite (HA) Orbital Implant
Features 
  • Maintain Natural Lid Shape
    The implant must provide a means, such as the ability to receive a motility/support peg, to support the weight of the artificial eye to prevent damage to the delicate muscles of the lower lids over time
  • Light Weight
    The implant must be light in weight.
  • Porosity
    The implant must allow vascular orbital tissues to invade its structure to: a) lock it into place and prevent migration, b) allow it to fight infections from within the implant via the vascular bed infiltrating the implant, and c) support "healing from within" of any defect in the conjunctival-Tenon's closure
  • True Integration
    The implant must be directly integrated (e.g., via a peg) with the artificial eye to allow direct transfer of all available movement from the rectus muscles to the artificial eye
  • Natural Biocompatibility
    The implant must be a natural material and readily accepted by the tissues of the orbit to prevent "synthetic implant syndrome" i.e., pseudocapsule formation around the implant. This pseudocapsule is the body's way of walling off a foreign material.
Description The Bio-eye hydroxyapatite (HA) orbital implant was conceived by Arthur C. Perry, M.D., in the early 1980s, after a comprehensive review of the literature on orbital implants, which included the earliest manuscripts dating back to 1885 (Mules 1885). This review, along with an ongoing dissatisfaction with the performance of contemporary implants, allowed Perry to identify the performance characteristics of an ideal orbital implant and, perhaps more importantly, led to the identification of the key physical design variables that accounted for the relative success or failure of a given orbital implant.

The natural hydroxyapatite orbital implant has the longest successful track record of any known implant material that can successfully accommodate a motility/support peg, which directly connects the artificial eye to the implant. The complete interconnected porosity filled with fibrovascular ingrowth makes this possible. The motility/support peg supports the weight of the prosthesis while simultaneously ensuring transfer of any socket movement directly to the prosthesis.

The Coated Bio-eye Hydroxyapatite Orbital Implant became available in November 2003. This is the most scientifically engineered and medically designed implant in the world.

Info Bio-Eye Orbital Implants
Customer Service:
Web site: http://www.ioi.com/

Related medicine products :

1. ApaPore Hydroxyapatite Bone Graft Substitute
2. Orbital Plates
3. Ocu-pore Porous Orbital Implants
4. 1.5mm Orbital Floor Plates
5. MEDPOR Orbital Rim Implant (IMORI)
6. MEDPOR Orbital Rim Onlay Implants
7. MEDPOR Orbital Rims
8. MEDPOR Inferior Orbital Rims
9. MEDPOR Superior Lateral Orbital Rim
10. Mesh-Wrapped Bioceramic Orbital Implant
11. Bioceramic Orbital Implants
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products:
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... content, records and case management solutions and services to both government and commercial ... Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. EDAC ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people ... the largest single-company convention to date for the state of Utah. , “We are ... tremendous event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of ...
(Date:9/2/2015)... ... ... G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab have ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
(Date:9/2/2015)... YORK , Sept. 2, 2015 Relmada ... novel therapies for the treatment of chronic pain, announced ... meetings at both the FBR Second Annual Healthcare Conference ... as follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor ...
(Date:9/2/2015)... Tumultuous market conditions – including changes in ... activity – have led more than half of today,s ... reps. This marks the first time that the number ... point, according to the spring 2015 AccessMonitor™ report ... . AccessMonitor™ aggregates sales-call records ...
(Date:9/2/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... development and commercialization of new cancer therapies, today ... "A Comparison of the Mechanisms and Cytotoxic ... Tumor Models Harboring Wild-type and Mutant p53," ...
Breaking Medicine Technology:Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4